Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a kidney transplant train the body to accept a mismatched organ?

NCT ID NCT03867617

Disease control Sponsor: Thomas Wekerle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether a combination of the recipient's own regulatory T cells, donor bone marrow, and the drug tocilizumab can help the immune system accept a living-donor kidney that is not a perfect match. The trial enrolls 12 adults scheduled to receive a kidney from a living donor. Participants receive the cell and drug therapy around the time of transplant, and researchers track safety and whether donor cells persist in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of the recipient's own expanded regulatory T cells, donor bone marrow infusion, and the drug tocilizumab
What this could lead to
If it works, this approach could one day help kidney transplant recipients accept their new organ with less lifelong anti-rejection medication.
What could go wrong
This is a small, early-phase trial with only 12 participants, so results may not apply broadly. The treatment could fail to produce tolerance, and participants still face standard transplant risks like rejection and infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

12 people

The number who actually took part.

Started

Aug 2019

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient has provided written informed consent. * Patient is 18 years or older. * Patient is a planned recipient of a living donor kidney transplant. * Patient is a planned recipient of an ABO blood group-compatible kidney graft. * Patient is a planned recipient of a kidney graft from a donor that is not HLA (human leukocyte antigen)-identical. * Patient is negative for DSA (donor-specific antibodies). * WOCBP (women of child-bearing potential) must have a negative pregnancy test at inclusion. * WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the study in such a manner that the risk of pregnancy is minimized. Exclusion Criteria: * Patient is EBV (epstein barr virus)-negative on serology. * Patient is HIV-positive or suffering from chronic viral hepatitis. * Patient is CMV (cytomegalo virus)-negative and receiving a kidney from a CMV-positive donor. * Positive T-cell lymphocytotoxic cross match. * Patient with prior kidney transplant or non-renal solid organ transplant. * Patient has a known contraindication to any of the protocol-specified treatments. * Patient had been diagnosed with a malignancy within 5 years prior to study entry, excluding non-metastatic basal or squamous cell carcinoma of the skin. * Female patients who are breast-feeding. * Female patients with a positive pregnancy test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplantation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplantation

Contacts and locations

Locations

  • Medical University of Vienna/Vienna General Hospital

    Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.